Avior Wealth Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,464
| Closed | -$940K | – | 1271 |
|
|
2021
Q3 | $940K | Buy |
5,464
+93
| +2% | +$12.2K | 0.08% | 193 |
|
|
2021
Q2 | $674K | Sell |
5,371
-253
| -4% | -$31.9K | 0.07% | 238 |
|
|
2021
Q1 | $762K | Sell |
5,624
-16
| -0.3% | -$2.07K | 0.08% | 217 |
|
|
2020
Q4 | $721K | Hold |
5,640
| – | – | 0.09% | 196 |
|
|
2020
Q3 | $634K | Buy |
5,640
+1,640
| +41% | +$163K | 0.09% | 192 |
|
|
2020
Q2 | $381K | Buy |
4,000
+510
| +15% | +$49.2K | 0.06% | 289 |
|
|
2020
Q1 | $313K | Sell |
3,490
-2,510
| -42% | -$195K | 0.06% | 265 |
|
|
2019
Q4 | $318K | Sell |
6,000
-920
| -13% | -$41.9K | 0.05% | 314 |
|
|
2019
Q3 | $273K | Hold |
6,920
| – | – | 0.05% | 316 |
|
|
2019
Q2 | $284K | Sell |
6,920
-340
| -5% | -$14.1K | 0.05% | 307 |
|
|
2019
Q1 | $338K | Buy |
7,260
+3,170
| +78% | +$139K | 0.07% | 255 |
|
|
2018
Q4 | $178K | Buy |
4,090
+50
| +1% | +$2.5K | 0.04% | 333 |
|
|
2018
Q3 | $231K | Buy |
4,040
+1,570
| +64% | +$77.2K | 0.05% | 313 |
|
|
2018
Q2 | $120K | Sell |
2,470
-1,290
| -34% | -$47K | 0.03% | 425 |
|
|
2018
Q1 | $147K | Sell |
3,760
-780
| -17% | -$33.2K | 0.03% | 395 |
|
|
2017
Q4 | $193K | Buy |
+4,540
| New | +$170K | 0.04% | 336 |
|
Avior Wealth Management's XLRN Position: Q4 2021 in Review
Avior Wealth Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 5,464 shares — an estimated $940K sold.
Avior Wealth Management first reported a position in XLRN in Q4 2017 and held it in 16 quarters. The position peaked at $940K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Avior Wealth Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Avior Wealth Management sold 5,464 Acceleron Pharma shares in Q4 2021, an estimated $940K.
- Avior Wealth Management first reported a position in Acceleron Pharma in Q4 2017 and held it in 16 quarters.
- Avior Wealth Management's Acceleron Pharma position peaked at $940K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Avior Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.